A New Era in Asthma Management: Assessment of Asthma Control

Kevin R. Murphy

Joel Solis

The University of Texas Rio Grande Valley

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub

Part of the Medicine and Health Sciences Commons

Recommended Citation

A New Era in Asthma Management: Assessment of Asthma Control

Kevin R. Murphy, MD; Joel Solis, MD

BURDEN OF DISEASE

Asthma is recognized as a chronic, heterogenous disease characterized by airway inflammation and a history of respiratory symptoms (e.g., wheeze, shortness of breath, chest tightness, or cough) that vary over time and in intensity. Variations are often triggered by factors such as exercise, allergen or irritant exposure, change in weather, or viral respiratory tract infections. Asthma symptoms and airflow limitation may resolve spontaneously or in response to treatment. Symptoms may be absent for weeks or months, yet airway hyperresponsiveness related to chronic airway inflammation usually persists.

Asthma is a common disease in children, adolescents, and adults that results in substantial morbidity and utilization of health care resources. In 2018, there were an estimated 5.5 million children and 19.2 million adults in the United States with asthma, of whom 45% had ≥1 asthma attack. In 2016, there were nearly 10 million office visits with asthma as a primary diagnosis. One-third (33.1%) of adults with asthma report their health as fair or poor. Anxiety, depression, and asthma control are independent predictors of diminished health-related quality of life in people with asthma.

The economic burden of asthma, including costs incurred by absenteeism and mortality, was estimated at $82 billion in 2013. By comparison, the total economic burden— including lost productivity— has been estimated at $330 billion for heart disease and stroke and $327 billion for diabetes. The 20-year estimated burden of direct and indirect costs associated with asthma is $964 billion, with a loss of 15.5 million quality-adjusted life-years in adolescents and adults.

A key factor contributing to the burden of disease associated with asthma is poor adherence to treatment by patients. A variety of additional factors contribute, including limited understanding among patients about asthma and its treatment, as well as poor patient-clinician communication. Discordance regarding asthma control is common between patients and clinicians. Patients often overestimate their asthma control or may tolerate symptoms indicative of poor control based on the belief that the symptoms are part of living with asthma. Collectively, these factors contribute to suboptimal asthma control.

ASSESSING ASTHMA CONTROL

Asthma control means the extent to which the effects of asthma either can be seen in the patient or have been reduced or resolved by treatment. Asthma control has 2 domains: symptom control and risk factors for future poor outcomes, particularly flare-ups (exacerbations). It is important to assess the patient’s future risk for exacerbations, even when symptom control is good. Risk factors for exacerbations that are independent of symptom control include a history of ≥1 exacerbation in the previous year, socioeconomic disadvantages, poor treatment adherence, incorrect inhaler technique, low lung function, smoking, and blood eosinophilia.

Many tools are available to assess asthma control and are listed in the TABLE. Of those tools, the Asthma Impairment and Risk Questionnaire (AIRQ) and Asthma Control Test (ACT) are validated for patients age ≥12 years and have numerically scored questions providing total scores and cut points for varying levels of asthma control. The ACT (FIGURE 1) is limited to assessing symptom control with no direct measure of future risk.
in the previous year, suggesting limitations in using ACT as a sole measure of asthma control. Inclusion of the wide array of items in AIRQ to assess both symptom control and future risk identified many patients with exercise limitations and exacerbations that were characterized by acute treatment with oral corticosteroids or emergency department/unplanned office visits, events that are not assessed by the ACT or many other asthma control tools for patients age ≥12 years.

MANAGEMENT OF PATIENTS WITH UNCONTROLLED ASTHMA

The most up-to-date recommendations for managing patients with uncontrolled asthma (discussed below) were released by Global Initiative for Asthma (GINA) in 2020.1 Updated recommendations by the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report-4 (EPR-4) have been circulated in draft form and are currently being finalized.

Patients found to have uncontrolled asthma should continue to receive care that meets their clinical and personal needs and capabilities. A key step in managing a patient with uncontrolled asthma is to confirm the asthma diagnosis. If not done as part of assessing asthma control, lung function should be measured. In addition, reevaluation of asthma control is appropriate to ensure that the treatment plan is consistent with recommended evidence-based therapy.

Attention should be paid to verify that all modifiable...
**FIGURE 1. Asthma Control Test**

Asthma Control Test™ provides a numerical score to help you and your healthcare provider determine if your asthma symptoms are well controlled.

**Step 1:** Write the number of each answer in the score box provided.

**Step 2:** Add up each score box for the total.

**Step 3:** Take the completed test to your healthcare provider to talk about your score.

IF YOUR SCORE IS 19 OR LESS, Your asthma symptoms may not be as well controlled as they could be.

**No matter what the score, bring this test to your healthcare provider to talk about the results.**

NOTE: If your score is 15 or less, your asthma may be very poorly controlled. Please contact your healthcare provider right away. There may be more you and your healthcare provider could do to help control your asthma symptoms.

---

*This Web Site has been developed as a service of GlaxoSmithKline. Like any other service, in spite of our (GSK) best efforts the information in this Web Site may become out of date over time. Nothing on this Web Site should be construed as the giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important that you rely only on the advice of a health care professional to advise you on your specific situation. GlaxoSmithKline accepts no liability for the accuracy or completeness or use of, nor any liability to update, the information contained on this Web Site. These materials are provided "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.*

[https://www.asthma.com/additional-resources/asthma-control-test.html]
FIGURE 2. Asthma Impairment and Risk Questionnaire

Asthma Impairment and Risk Questionnaire (AIRQ™)

For use by health care providers with their patients 12 years and older who have been diagnosed with asthma. AIRQ™ is intended to be part of an asthma clinic visit. Please answer all of the questions below.

In the past 2 weeks, has coughing, wheezing, shortness of breath, or chest tightness:
1. Bothered you during the day on more than 4 days?
2. Woke you up from sleep more than 1 time?
3. Limited the activities you want to do every day?
4. Caused you to use your rescue inhaler or nebulizer every day?

In the past 2 weeks:
5. Did you have to limit your social activities (such as visiting with friends/relatives or playing with pets/children) because of your asthma?
6. Did coughing, wheezing, shortness of breath, or chest tightness limit your ability to exercise?
7. Did you feel that it was difficult to control your asthma?

In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness:
8. Caused you to take steroid pills or shots, such as prednisone or Medrol®?
9. Caused you to go to the emergency room or have unplanned visits to a health care provider?
10. Caused you to stay in the hospital overnight?

Total YES Answers

What Does My AIRQ™ Score Mean?
The AIRQ™ is meant to help your health care providers talk with you about your asthma control. Whatever your AIRQ™ score (total YES answers), it is important for your health care team to discuss the number and answers to each of the questions with you. All patients with asthma, even those who may be well-controlled, can have an asthma attack. As asthma control worsens, the chance of an asthma attack increases. Only your medical provider can decide how best to assess and treat your asthma.

Health Care Providers and Patients Take Action Together to Control Asthma

[http://www.airqscore.com]

[AIRQ™ is a trademark of AstraZeneca. The AIRQ™ is reproduced with permission from AstraZeneca. AstraZeneca is the copyright owner of the AIRQ™. However, third parties will be allowed to use the AIRQ™ free of charge. The AIRQ™ must always be used in its entirety. Except for limited reformating the AIRQ™ may not be modified or combined with other instruments without prior written approval. The ten questions of the AIRQ™ must appear verbatim, in order, and together as they are presented and not divided on separate pages. All copyright and trademark information must be maintained as it appears on the bottom of the AIRQ™ and on all copies. The layout of the final authorized AIRQ™ may differ slightly, but the item wording will not change.]
ASTHMA MANAGEMENT

Risk factors have been identified and appropriate treatment instituted. This strategy is particularly important for risk factors that do not require or respond to a step-up in controller treatment. Examples include poor inhaler technique, suboptimal treatment adherence, home and workplace atopic and irritant triggers, tobacco use or exposure, and comorbidities such as gastroesophageal reflux disease, nasal polyposis, obesity, and sleep apnea.

Patient understanding of asthma, treatment goals, and treatment options should be assessed and reinforced with further education. A guide for patients and families is available from the National Heart, Lung, and Blood Institute (https://www.nhlbi.nih.gov/files/docs/public/lung/SoYou-HaveAsthma_PRINT-reduced-filesize.pdf). Patients should be educated about the importance of the use of anti-inflammatory medications, because only 39% of adults and 40% of children with asthma use a long-term control medication.27 In addition, patient education should include the importance of reducing the risk of exposure to allergens or other sensitizing agents.1

The patient’s familiarity with their written asthma action plan should be assessed routinely, as this is an indicator of the patient’s ability to self-manage their asthma. Patients should be invited to share difficulties they may be having with the action plan or any other issues that may affect treatment adherence. If difficulties are identified, focus a collaborative discussion on finding a solution that is acceptable to the patient and that they are able and willing to implement. Sample written action plans are available from the National Heart, Lung, and Blood Institute (https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/asthma-action-plan) and GINA (https://ginasthma.org/wp-content/uploads/2019/01/GINA-Implementation-Toolbox-2019.pdf).

Objective assessment of inhaler technique is especially important because proper technique has a direct impact on patient health outcomes and treatment tolerability.28 Because administration errors with inhaled medications by patients are common, and clinicians are often unfamiliar with proper administration technique,29-33 the use of authoritative patient education resources demonstrating proper inhaler technique – such as those by the Centers for
Disease Control and Prevention – is recommended (https://www.cdc.gov/asthma/inhaler_video/default.htm).

PHENOTYPES AND BIOMARKERS

The heterogeneous nature of asthma and the many clusters of demographic, clinical, and/or pathophysiologic characteristics point to the importance of recognizing asthma phenotypes and endotypes in patients with uncontrolled asthma.1,34 Identifying the asthma phenotype is especially important for patients with moderate or severe uncontrolled asthma because some phenotype-specific treatments are available. For example, omalizumab is indicated for allergic asthma, whereas benralizumab, dupilumab, mepolizumab, and reslizumab are indicated for the eosinophilic phenotype.

Two peripheral biomarkers (Immunoglobulin E [IgE] and eosinophils) are particularly helpful in identifying asthma phenotype and guiding treatment. IgE is the predominant biomarker for allergic asthma that is produced early in the allergic cascade.35 The serum IgE level correlates closely with the presence and severity of asthma in adults, adolescents, and children.36,37

Owing to the inflammatory nature of asthma, eosinophils are recruited through the complex interaction of cytokines and other inflammatory mediators.38,39 The blood eosinophil count is more closely correlated with risk of asthma exacerbations.40 Symptom severity is increased in eosinophilic asthma, although symptom severity is not identified exclusively with eosinophilia.35,41-43

KEY ASTHMA TREATMENT RECOMMENDATIONS

Global Initiative for Asthma

GINA was implemented in 1993 to develop a network of individuals, organizations, and public health officials for the dissemination of information related to the care of patients with asthma.44 Another key purpose of GINA was to provide a mechanism to incorporate the results of scientific evidence into asthma care, leading to the first GINA report in 1995, developed in collaboration with the National Heart, Lung, and Blood Institute. The report has been updated several times, and recently on a yearly basis, to reflect the totality of the evolving evidence. Consequently, the GINA report provides comprehensive recommendations for the diagnosis and treatment of patients with asthma.1 Key recent changes include the recommendations that all adults and adolescents should be treated with an inhaled corticosteroid (ICS) to reduce the risk of severe exacerbations. In addition, treatment with only a short-acting beta₂-agonist is no longer recommended.

Specific recommendations for step-up therapy are beyond the scope of this article, as recommendations depend on the patient’s current therapy and asthma control. Nonetheless, step-up therapy involves either increasing the dose of the current controller therapy or adding another controller medication. For example, a patient aged ≥12 years whose asthma is uncontrolled with the combination of a low-dose ICS plus a long-acting beta₂-agonist may benefit from increasing to a medium-dose ICS plus a long-acting beta₂-agonist (FIGURE 3).1 Discussions with a patient about step-up therapy should consider affordability, as asthma care in the United States is associated with high rates of cost-related underuse of medications. Although the reason is unclear, suboptimal adherence to asthma medications does not appear to be directly related to income.45 Any step-up should be regarded as a therapeutic trial, and the response reviewed after 2 to 3 months.1 In some cases, for example, during viral infection or seasonal allergen exposure, the duration of step-up therapy may be only 1 to 2 weeks.

National Asthma Education and Prevention Program

The NAEPP was initiated in 1989 to address the growing health problem of asthma in the United States.46 From the beginning, the NAEPP has involved a wide variety of stakeholder groups and organizations with the general goals to raise awareness among all asthma stakeholders about the importance of asthma, as well as to promote effective, evidence-based treatment so as to reduce the disease burden. The first guideline report was published in 1991, with subsequent updates and comprehensive revisions. The last comprehensive revision was the Expert Panel Report-3 in 2007. The EPR-4, which is a limited revision that focuses on 6 topics, is being finalized.47

SUMMARY

Asthma is often uncontrolled in patients of all ages and is frequently unrecognized, resulting in a significant burden of disease. Consequently, assessing asthma control at every opportunity is critical. A wide variety of tools to assess asthma control are available; however, many have clinically important limitations to their use. The AIRQ was developed recently to be more widely applicable, by assessing both symptom control and future risk domains. In patients with uncontrolled asthma, step-up therapy is generally required using evidence-based recommendations for treatment provided in the GINA 2020 report and soon-to-be-released NAEPP EPR-4 report.

REFERENCES


Supplement to The Journal of Family Practice | Vol 69, No 7 | SEPTEMBER 2020 S19


